{"id":18244,"date":"2021-12-27T10:38:31","date_gmt":"2021-12-27T18:38:31","guid":{"rendered":"https:\/\/marketdepth.com\/?p=18244"},"modified":"2021-12-27T10:38:32","modified_gmt":"2021-12-27T18:38:32","slug":"bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/","title":{"rendered":"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study"},"content":{"rendered":"\n

BridgeBio Pharma, Inc. (NASDAQ: BBIO) has reported<\/a> results from Month 12 of ATTRibute-CM.\u00a0 ATTRibute-CM is a global phase 3 study that investigates acoramidis for treatment of sympromatic transthyretin amyloid cardiomyopathy.\u00a0 The study displayed decline in both arms of ATTRibute-CM, similar to expected functional decline in healthy elderly adults.\u00a0 \u201cThis result is disappointing and baffling. I am, along with many others, searching for answers regarding the 6MWD,\u201d said Neil Kumar, Ph.D., founder and CEO of BridgeBio. \u201cThe results do not appear to be due to a baseline imbalance. The hypotheses we are currently evaluating include context bias, training bias, and an evolution in diagnosis and standard of care. The drug does appear to be pharmacologically active and well-tolerated, and we observed improvement on quality of life with promising trends on adverse events leading to death. The drug seems to be doing what we are asking of it. If we observe enough clinical outcome events at Month 30, I am still hopeful that we will demonstrate the benefit of acoramidis treatment.\u201d<\/p>\n\n\n\n

\u201cAlthough these results were not what we hoped, the most important moment in this trial will be the Part B readout at 30 months, where we will see the effects of acoramidis on all-cause mortality and cardiovascular hospitalizations. From what I\u2019ve seen so far, I remain enthusiastic about getting to that endpoint.\u201d<\/p>Daniel Judge, M.D., professor in the Division of Cardiology at the Medical University of South Carolina, and co-chair of the ATTRibute-CM Steering Committee<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"BridgeBio Pharma, Inc. (NASDAQ: BBIO) has reported results from Month 12 of ATTRibute-CM.\u00a0 ATTRibute-CM is a global phase 3 study that investigates acoramidis for treatment of sympromatic transthyretin amyloid cardiomyopathy.\u00a0 The study displayed decline in both arms of ATTRibute-CM, similar to expected functional decline in healthy elderly adults.\u00a0 \u201cThis result is disappointing and baffling. I… View Article<\/a>","protected":false},"author":3,"featured_media":18195,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,31,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nBridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"BridgeBio Pharma, Inc. (NASDAQ: BBIO) has reported results from Month 12 of ATTRibute-CM.\u00a0 ATTRibute-CM is a global phase 3 study that investigates acoramidis for treatment of sympromatic transthyretin amyloid cardiomyopathy.\u00a0 The study displayed decline in both arms of ATTRibute-CM, similar to expected functional decline in healthy elderly adults.\u00a0 \u201cThis result is disappointing and baffling. I... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-27T18:38:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-27T18:38:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/12\/CancerResearch.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study\",\"datePublished\":\"2021-12-27T18:38:31+00:00\",\"dateModified\":\"2021-12-27T18:38:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Biotechnology\",\"Business\",\"Headlines\",\"Healthcare\",\"Investing\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/\",\"url\":\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/\",\"name\":\"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2021-12-27T18:38:31+00:00\",\"dateModified\":\"2021-12-27T18:38:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News & Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study - MarketDepth","og_description":"BridgeBio Pharma, Inc. (NASDAQ: BBIO) has reported results from Month 12 of ATTRibute-CM.\u00a0 ATTRibute-CM is a global phase 3 study that investigates acoramidis for treatment of sympromatic transthyretin amyloid cardiomyopathy.\u00a0 The study displayed decline in both arms of ATTRibute-CM, similar to expected functional decline in healthy elderly adults.\u00a0 \u201cThis result is disappointing and baffling. I... View Article","og_url":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2021-12-27T18:38:31+00:00","article_modified_time":"2021-12-27T18:38:32+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/12\/CancerResearch.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study","datePublished":"2021-12-27T18:38:31+00:00","dateModified":"2021-12-27T18:38:32+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Biotechnology","Business","Headlines","Healthcare","Investing","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/","url":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/","name":"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2021-12-27T18:38:31+00:00","dateModified":"2021-12-27T18:38:32+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/bridgebio-pharma-announces-12-month-results-from-phase-3-attribute-cm-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma Announces 12 Month Results from Phase 3 ATTRibute-CM Study"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News & Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18244"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=18244"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18244\/revisions"}],"predecessor-version":[{"id":18245,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18244\/revisions\/18245"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/18195"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=18244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=18244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=18244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}